The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, D1230, Boston, MA 02215, USA.
The advent of targeted agents for the treatment of advanced renal cell carcinoma has led to dramatic improvements in therapy. However, the chronic use of these medications has also led to the identification of new toxicities that require long-term management. Effective management of toxicity is needed to maximize the benefits of treatment and improve patients' quality of life. In addition, toxicity from these agents may affect treatment compliance, particularly with daily oral agents. This review delineates the toxicities that require monitoring, the underlying pathophysiology (when known), and treatments that may have benefits in relieving symptoms and side effects.
Written by:
Appleby L, Morrissey S, Bellmunt J, Rosenberg J. Are you the author?
Reference: Hematol Oncol Clin North Am. 2011 Aug;25(4):893-915.
doi: 10.1016/j.hoc.2011.05.004
PubMed Abstract
PMID: 21763973
UroToday.com Renal Cancer Section
